Aeglea BioTherapeutics (NASDAQ:AGLE) Lowered to Sell at StockNews.com

Posted by Defense World Staff on Jul 16th, 2023

Aeglea BioTherapeutics (NASDAQ:AGLE – Get Free Report) was downgraded by equities research analysts at StockNews.com from a “hold” rating to a “sell” rating in a research report issued on Sunday.

AGLE has been the subject of a number of other reports. Lifesci Capital lowered shares of Aeglea BioTherapeutics from an “outperform” rating to a “market perform” rating in a research report on Wednesday, April 12th. Wells Fargo & Company lowered shares of Aeglea BioTherapeutics from an “overweight” rating to an “equal weight” rating in a research report on Wednesday, April 12th. Finally, Jonestrading reissued a “hold” rating on shares of Aeglea BioTherapeutics in a research note on Wednesday, April 12th. One analyst has rated the stock with a sell rating, four have given a hold rating and one has assigned a buy rating to the company’s stock. According to MarketBeat, Aeglea BioTherapeutics has an average rating of “Hold” and a consensus price target of $1.88.

Aeglea BioTherapeutics Price Performance

Shares of NASDAQ AGLE opened at $0.56 on Friday. The stock has a market capitalization of $36.55 million, a PE ratio of -0.67 and a beta of 2.51. Aeglea BioTherapeutics has a one year low of $0.11 and a one year high of $1.56. The business’s fifty day moving average price is $0.25 and its 200-day moving average price is $0.33.

Aeglea BioTherapeutics (NASDAQ:AGLE – Get Free Report) last released its quarterly earnings data on Thursday, May 11th. The biotechnology company reported ($0.20) EPS for the quarter, missing the consensus estimate of ($0.19) by ($0.01). The business had revenue of $0.20 million during the quarter, compared to the consensus estimate of $0.17 million. Aeglea BioTherapeutics had a negative return on equity of 132.05% and a negative net margin of 6,678.20%. As a group, equities analysts expect that Aeglea BioTherapeutics will post -0.47 EPS for the current fiscal year.

Institutional Trading of Aeglea BioTherapeutics

Institutional investors have recently made changes to their positions in the stock. Walleye Capital LLC purchased a new stake in Aeglea BioTherapeutics in the 1st quarter worth approximately $312,000. Renaissance Technologies LLC lifted its stake in Aeglea BioTherapeutics by 283.5% in the second quarter. Renaissance Technologies LLC now owns 582,444 shares of the biotechnology company’s stock worth $294,000 after acquiring an additional 430,576 shares during the period. Geode Capital Management LLC lifted its stake in Aeglea BioTherapeutics by 52.4% in the fourth quarter. Geode Capital Management LLC now owns 600,455 shares of the biotechnology company’s stock worth $270,000 after acquiring an additional 206,435 shares during the period. Millennium Management LLC boosted its holdings in Aeglea BioTherapeutics by 23.1% in the second quarter. Millennium Management LLC now owns 521,915 shares of the biotechnology company’s stock valued at $264,000 after acquiring an additional 98,001 shares in the last quarter. Finally, Charles Schwab Investment Management Inc. increased its position in Aeglea BioTherapeutics by 7.4% during the 1st quarter. Charles Schwab Investment Management Inc. now owns 106,810 shares of the biotechnology company’s stock valued at $246,000 after purchasing an additional 7,333 shares during the period. Hedge funds and other institutional investors own 63.20% of the company’s stock.

Aeglea BioTherapeutics Company Profile

(Get Free Report)

Aeglea BioTherapeutics, Inc, a clinical-stage biotechnology company, designs and develops human enzyme therapeutics for the treatment of rare metabolic diseases. The company's therapeutic candidates include pegtarviliase, a polyethylene glycol modified, which is in Phase I/II clinical trial for the treatment of patient with homocystinuria; and pegzilarginase, a recombinant human Arginase 1 that is in Phase III PEACE trial to evaluate the safety and efficacy for the treatment of Arginase 1 deficiency.